Success of Pharma companies is dependent on new products it is able to bring out from time to time. Routine patent expirations dent the sales, and the new drugs help the company fill those revenue / income gaps. Roche is heavily into research in oncology. It has several drugs in the pipeline, and has also filed patents for many. The patents filed by Roche in this segment include those for non-Hodgkin's lymphoma subcutaneous formulation, 1st line metastatic non-small cell lung cancer, EGFR mutation positive, pretreated HER2-positive metastatic breast cancer, relapsed ovarian cancer, platinum-sensitive, early HER2-positive breast cancer, subcutaneous formulation, non-Hodgkin's lymphoma fast infusion, advanced basal cell carcinoma and metastatic melanoma. This is a very competitive field with most of the major pharma companies highly committed to oncology. Big companies and small companies like Senesco Technologies (SNTI) are trying novel ways and approaches for treatment of the disease. Oncology is the main segment for pharma revenues of Roche with 61% of its sales in 2012 coming from anti cancer drugs. In 2011 this was 59% indicating its increasing importance. The oncology segment revenues have grown by 9% for Roche compared with its overall growth in pharma sales of 5%. As per the annual report, the division benefited from strong growth in the US (+7%), China (+27%) and Brazil (+11%). Sales growth was primarily driven by six products which represent 60% of the portfolio. The recently launched Zelboraf also contributed to the growth. Overall, tor 2012 the sales CHF 45.499 billion compared with CHF 42.531 billion (a growth of 6.9%). The net income increased from CHF 9.343 billion to CHF 9.539 billion (a growth of 2%). The dividends per share increased from CHF 6.80 to CHF 7.35 (8% growth). In the six month ending December 31,2012 the sales were CHF 23.076 billion compared with CHF 22.423 billion.